1. Home
  2. CLRO vs INDP Comparison

CLRO vs INDP Comparison

Compare CLRO & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearOne Inc. (DE)

CLRO

ClearOne Inc. (DE)

N/A

Current Price

$6.17

Market Cap

17.0M

Sector

Technology

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$1.10

Market Cap

125.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLRO
INDP
Founded
1983
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0M
125.2M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
CLRO
INDP
Price
$6.17
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.6M
778.5K
Earning Date
05-18-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$46,067,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.59
N/A
52 Week Low
$2.71
$0.92
52 Week High
$16.50
$8.57

Technical Indicators

Market Signals
Indicator
CLRO
INDP
Relative Strength Index (RSI) N/A 38.26
Support Level N/A $0.92
Resistance Level N/A $2.95
Average True Range (ATR) 0.00 0.18
MACD 0.00 0.06
Stochastic Oscillator 0.00 33.33

Price Performance

Historical Comparison
CLRO
INDP

About CLRO ClearOne Inc. (DE)

ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: